The design of peptide-based subunit vaccine formulations for the direct delivery of tumor
antigen peptides (Aps) to dendritic cells (DCs) localized within draining lymph nodes (DLNs) …

Dendritic cells (DCs) are increasingly used in cancer vaccines due to their ability to regulate
T-cell immunity. Major limitations associated with the present DC adoptive transfer …

Targeting dendritic cells (DCs), either ex vivo (Ex. Sipuleucel-T) or in vivo, for stimulating
cellular immunity has been a leading approach for cancer vaccines. We have rationally …

Despite the extensive development of peptide-based tumor antigen vaccines, the field still
faces up enormous challenges from lacking clinical efficacy. Here, we report the design and …

Exogenous antigens processed in the cytosol and subsequently cross-presented on major
histocompatibility complex class I (MHC-I) molecules activate cytotoxic CD8+ lymphocytes …

Cancer immunotherapies such as tumor vaccines, chimeric antigen receptor T cells and
immune checkpoint blockades, have attracted tremendous attention. Among them, tumor …

The immune system is a powerful resource for the eradication of cancer, but to overcome the
low immunogenicity of tumor cells, a sufficiently strong CD8+ T cell-mediated adaptive …

Peptide-based vaccines, which form one of the most potent vaccine platforms, offer
exclusive advantages over classical vaccines that use whole organisms or proteins …

Cancer vaccines targeting patient-specific tumor neoantigens have recently emerged as a
promising component of the rapidly expanding immunotherapeutic armamentarium …

Nanotechnology-based antigen delivery has been developing as a vaccine strategy due to
its dose-sparing and prolonged antigen presentation features. In the current study, we …